Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
54.32
-1.45 (-2.60%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
65
66
Next >
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.
Via
InvestorPlace
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023
Via
Benzinga
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
December 25, 2023
Via
Benzinga
Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
December 24, 2023
Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.
Via
Talk Markets
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
December 24, 2023
These two biotech stocks could be poised for a trend reversal.
Via
The Motley Fool
What To Do With High-Flying Tech At The Start Of 2024?
December 23, 2023
Here, I will do two things. First, I will look at the macro backdrop at the start of 2024, and secondly I will run through the portfolio, how it is doing, and what changes I have made, or intend to...
Via
Talk Markets
Dow Edges Lower; Nike Sales Miss Estimates
December 22, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
HBM Gets Health Boost From Drug Licensing Deals
December 22, 2023
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05...
Via
Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
December 22, 2023
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Gold Moves Higher; US Consumer Sentiment Improves In December
December 22, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst
December 22, 2023
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill
Via
Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Friday Session
December 22, 2023
Via
Investor Brand Network
Exposures
COVID-19
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics
December 22, 2023
Via
Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
December 22, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal
December 22, 2023
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n
Via
Benzinga
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
December 22, 2023
Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis.
Via
Investor's Business Daily
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
December 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
December 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 Potential Turnaround Stocks to Buy for Big Rewards in 2024
December 20, 2023
There was plenty to get excited about in 2023 and even more to get excited about with turnaround stocks in the new year.
Via
InvestorPlace
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
7 Stocks with Strong Insider Buying: December 2023
December 17, 2023
Here are just a few of the top stocks with strong insider buying that all investors may want to watch heading into 2024.
Via
InvestorPlace
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.